This work is licensed under a Creative Commons Attribution 4.0 International License.
DPMI-δ-F
General Information
DRACP ID DRACP01440
Peptide Name DPMI-δ-F
Sequence TAWYANFⓍKLLⓍ
Sequence Length 12
UniProt ID Not available
PubChem CID Not available
Origin Synthetic construct
Type Synthetic peptide
Classification
Active ACP Cancer targeted peptides Stapled Peptides MDM2/MDMX antagonists
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target MDM2, MDMX
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Cyclic (Stapled)
Disulfide/Other Bond Stapled: Ⓧ(8) and Ⓧ (12) are cross-linked by hydrocarbon stapling
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification Ⓧ(8)=(S)-2- (4'-pentenyl)alanine or (R)-2- (4'- pentenyl)alanine; Ⓧ(12)=(S)-2- (4'-pentenyl)alanine or (R)-2- (4'- pentenyl)alanine
Chiral L
Physicochemical Information
Formula C67H97N15O16
Absent amino acids CDEGHIMPQRSV
Common amino acids A
Mass 156500
Pl 9.3
Basic residues 1
Acidic residues 0
Hydrophobic residues 8
Net charge 1
Boman Index 749
Hydrophobicity 60.83
Aliphatic Index 98.33
Half Life
Mammalian: 1.1 hour
Yeast: 3 min
E.coli: >10 hour
Extinction Coefficient cystines 6990
Absorbance 280nm 635.45
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US20120328692A1
Patent Title Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.
Other Iinformation Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status: Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.